SOPHiA GENETICS 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- SOPHiA GENETICS reported Q3 2026 revenue of $24.3 million, up 25% year over year and 26% on a constant currency basis, compared with $19.5 million in the 3rd quarter of 2025.
- The platform processed a record 118,000 analyses, up 19% year over year; the network covered 75 countries and 551 connected institutions as of September 30th, 2026.
- U.S. revenue grew 41%, North America grew 45%, Asia Pacific grew 33%, Norway revenue grew over 200%, and UK revenue grew over 100% year over year.
- Application volumes increased 30% for solid tumor, 29% for rare disorders, and 28% for heme/onc; liquid biopsy analyses rose more than 100% year over year to 4,200 and were up 41% sequentially versus Q2 levels.
- SOPHiA GENETICS signed 30 new logos in Q3 and had 551 core genomic customers, up from 488 in the prior year period; net dollar retention was 118%, and annualized revenue churn was less than 1%.
- Gross profit was $15.9 million, up 23%, and gross margin was 65.7%, compared with 66.3% in the 3rd quarter of 2025; adjusted gross profit was $17.6 million and adjusted gross margin was 72.8%, compared with 73.1%.
- Operating loss was $17.8 million, compared with $17.9 million in the prior year period; adjusted EBITDA loss was $6.1 million, improving 31% year over year from a loss of $8.8 million.
- Cash at quarter-end was $94 million, which management said was sufficient to meet long-term goals.
- The company signed a collaboration with a top 10 biopharma company to develop a multimodal AI predictor for bladder cancer patients’ likelihood of benefiting from immunotherapy, and continued work on two diagnostic programs with AstraZeneca.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter 2026 Earnings Conference Call. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. I would now like to turn the conference call over to Kellen Sanger, SOPHiA GENETICS Head of Strategy.
You may begin. Thank you, and good morning, everyone.
Welcome to the SOPHiA GENETICS Third Quarter 2026 Earnings Conference Call. Joining me today to discuss our results are Ross Muken, our Chief Executive Officer, and George Cardoza, our Chief Financial Officer. I would like to remind you that management will make statements during this call that are forward-looking statements within the meanings of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release issued by SOPHiA GENETICS today and in the documents and reports filed by SOPHiA GENETICS from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures.
A reconciliation of IFRS to non-IFRS measures is included in today's earnings press release, which is available on our website. With that, I will now turn the call over to Ross.
Thanks, Kellen, and good morning, everyone. Q3 was another strong quarter for SOPHiA. We delivered 25% year-over-year revenue growth as demand for our platform continues to expand. Growth in the U.S. market remained robust. New products in liquid biopsy and solid tumor continue to gain adoption, and new biopharma collaborations are establishing SOPHiA as a trailblazer in bringing clinical intelligence to patients around the globe. In addition to the strong growth, we also improved adjusted EBITDA materially in the third quarter by again dropping nearly 60% of our incremental revenue growth down to the bottom line, bringing us closer to profitability. Today, I will update you on each of these areas and provide more details on the exciting path ahead. SOPHiA was founded with a vision to transform the world's healthcare data into actionable clinical intelligence for providers and patients.
We started in genomics, where we've established ourselves as one of the largest diagnostic companies in the world. In Q3, the SOPHiA network performed 118,000 analyses on our platform, up 19% since last year. In other words, we analyzed roughly 40,000 patients per month across a network that spans 75 countries and 551 connected institutions globally. That network and the data flowing through it has allowed us to build one of the most sophisticated intelligence engines in healthcare. Every analysis run on our platform teaches our AI something new. It learns from a real-time, real-world dataset that is unmatched in its breadth and diversity, including thousands of clinical contexts from patients in over 75 countries. The learning doesn't stop with the data. Every day, pathologists, oncologists, and scientists across our community review insights, flag cases, and feed their expertise back into the platform.
The result is something no institution could build on its own. We call it collective intelligence. Over the last several months, demand for our intelligence tools has been accelerating. Today, I'll touch briefly on two areas where we're seeing outsized growth: the U.S. market and liquid biopsy. In Q3, we delivered 41% revenue growth in the U.S. market. The growth has been especially impressive given the scale of our U.S. business, which is now our largest market globally. Based on the strong demand we're seeing, that growth is well-positioned to continue. Recently signed major accounts, including Northwell, Igenomix, and a major West Coast health system, are scheduled to ramp significantly in the fourth quarter and into 2027. New signings also remain strong. In Q3 alone, we signed PathGroup, one of the largest physician-led pathology providers in the U.S., to Solid Tumor and HemOnc applications.
We also signed the University of Arkansas for Medical Sciences, the state's only health sciences university, for HemOnc. Beyond landing new accounts, our expand engine was strong as well. In Q3, the University of North Carolina Medical Center, a longstanding partner of SOPHiA, added additional applications across HemOnc, Hereditary Cancer, and Rare Disorders testing. These wins, along with our strong momentum in the U.S., reflect a broader trend. Over the past 12 months, we've seen an inflection in U.S. growth. Reimbursement rates are rising, denial rates are improving, and sequencing costs continue to drop. These dynamics have created favorable economic conditions for hospitals and labs to launch their own testing capabilities. Large central labs have proven that genomic testing is highly profitable, and now providers want to participate. SOPHiA makes that possible. We enable institutions to launch their own testing in-house.
We also empower institutions to retain control of their patient data, an increasingly valuable asset in the care ecosystem. Together, these trends are driving significant demand for our platform in the U.S. and beyond, as institutions look for intelligence tools to help them transform their data into actionable insights while also driving beneficial economics. The second major growth driver in the third quarter was new products. Bringing compelling products to our customers is critical for the widespread adoption of our platform. However, building products that work in labs across the globe is not easy. In 2023, we launched a revolutionary new liquid biopsy test, MSK-ACCESS, which allows any institution in the world to bring liquid biopsy testing to their institution. Making this test perform reliably required innovative new AI techniques to ensure accuracy and consistency. That investment is now paying off.
In Q3, we performed 4,200 liquid biopsy analyses globally, up more than 100% year-on-year and 41% sequentially versus Q2 levels. Looking ahead, we expect the liquid biopsy business to continue ramping, offering a meaningful catalyst for future growth. To date, we have signed more than 85 institutions to the application, including 6 in the third quarter alone. Of these new signings, a large number are currently implementing the platform and ramping usage. Unlike the U.S., liquid biopsy is an emerging technology in the rest of the world. As a leader in liquid biopsy outside of the U.S., SOPHiA and its growing network are well-positioned to capture this growth as adoption increases. To accelerate the ex-U.S. adoption trend, we are making a series of strategic investments.
This includes adding a new medical affairs function focused on generating evidence, demonstrating clinical utility, and advocating for the adoption of liquid biopsy testing across Europe, Asia, and Latin America. I look forward to sharing more on the team's progress and the growing demand for liquid biopsy in the quarters ahead. As our genomics footprint continues to expand and our network becomes larger, biopharma companies increasingly have come to recognize the value of our unique global reach and the data being streamed through our platform. This has resulted in a series of large signings with biopharma over the past 9 months, covering areas such as patient selection and stratification, companion diagnostics, foundational model building, real-world evidence, and the sponsored deployment of our tests. This quarter, I am proud to announce that the success is continuing.
During the quarter, we signed a major new collaboration with a top 10 biopharma company to develop a multimodal AI predictor to help identify which bladder cancer patients are most likely to benefit from immunotherapy. The project leverages SOPHiA's deep expertise in clinical intelligence, as well as our proprietary data, to build two complementary predictive models aimed at understanding patient response to a targeted therapy. Congratulations to the team on this win. This new business builds on the progress discussed last quarter when we announced the signing of not one, but two diagnostic programs with AstraZeneca, the first in SOPHiA's history. The first CDx program aims to develop a key solid tumor application into a decentralized companion diagnostic for patients with prostate cancer. We announced additional details on this program last month, including that the test will incorporate Myriad Genetics' novel prostate cancer-specific genomic instability score capability into the technology.
The second CDx program will leverage a hematological oncology application to support a therapy for patients with blood cancer. Together, these CDxs demonstrate the value of SOPHiA's network. For biopharma, the hardest part of a companion diagnostic isn't proving the biomarker works. It's getting the test to patients who need it, everywhere they are, at the moment a treatment decision is being made. That's the problem SOPHiA was built to solve. Our platform already sits inside hundreds of hospitals and laboratories across more than 70 countries, analyzing genomic data locally and consistently. This means that a CDx developed with us doesn't depend on shipping samples to a single central lab or waiting weeks for a result. It launches where oncologists are already working. Because the same platform brings together genomic, radiomic, and clinical data on one patient, you aren't limited to a single analyte test.
You can build software as a medical device that reflects how disease actually behaves across modalities, and over time, refine it as real-world evidence that flows back from the same network. The result is a diagnostic that reaches more patients faster, generates evidence continuously, and travels with your therapy into every market you enter. That is what clinical intelligence means in practice, and it is why partners who want their drugs to reach the right patient on day one are choosing to build with SOPHiA. To conclude, our commercial momentum keeps building. New geographies, exciting new products, and expanded relationships with biopharma offer meaningful catalysts for future growth. Given these factors, along with the dynamics we are seeing in our end markets, we now expect our full year 2026 revenue to be at the upper end of the previously issued guidance range of $94 million-$96 million.
The updated outlook reflects strong business performance, partially offset by the impact of foreign exchange. Furthermore, as we continue to grow, it is critical that we do so in a sustainable way. In the third quarter, we improved adjusted EBITDA by an impressive 31% year-over-year, dropping nearly 60% of our incremental revenue down to the bottom line. This performance represents the natural operating leverage of our business. Our tech-first, AI-native approach, built on a highly efficient intelligence platform, scales quickly without a proportional increase in cost. We remain fully committed to profitable growth. As previously stated, we expect to keep converting growth into further improvement in adjusted EBITDA in the fourth quarter and to cross over to positive adjusted EBITDA in the second half of next year. Underneath it all is a growing network of institutions relying on SOPHiA to turn complex data into clinical intelligence.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
